Latest News

Scotland's Pharmacells Group creates 12 new jobs at BioCity Scotland following acquisition by Precious Cells Group, London.

18 August 2014

The recent acquisition of Pharmacells by Precious Cells Group (PCG) from London will see the creation of an additional 12 jobs at Newhouse Scotland where the company is based at BioCity Scotland. Pharmacells was the first company to take a tenancy in the highly successful life sciences hub in 2012. New jobs will also be created in West London, where PCG currently employ 25 staff based on the Brunel Science Park.

The acquisition was motivated by Pharmacells™ "Oristem®" (Patented) stem cell harvesting process, collection and storage service, invented in Scotland, which will let PCB accelerate its growth into initiating clinical trials. The group company estimates that this acquisition will boost revenues by up to £3m in the first year, £7m in the second year and over £15m in year three.

Pharmacells™ patented Oristem® technology enables stem cells to be collected from adult blood to allow an individual’s own cells to be used in treatment. It is the only such system to offer this disruptive stem cell isolation facility available anywhere in the world and is the most straightforward and pain free method of storing adult stem cells. As a result, treatment using stem cells is expected to be far more effective as it lowers the risk of a body rejecting the cells.

Athol Haas, CEO and co-founder of Pharmacells says: "Partnering with Precious Cells Group, one of the world's leading stem cell consumer technology platform service providers, with its depth of resource and international reach will considerably enhance our efforts to market the Oristem® technology in the UK and globally."

"We are proud to have been one of the pioneers of a method to collect hundreds of millions of ultra-naïve stem cells from adult blood which can significantly improve the effectiveness of stem cell therapies and will help slow the spiralling cost of treating some of the most common and expensive medical conditions."

"Our re-location to Biocity has proved to be giant leap forwards for our company. The access to top class facilities without the huge infrastructure spend has allowed us to emerge as a leading player in Scottish Life Sciences. It has also proved vital to PCG as the quality of our facility is a key advantage for their expansion plan as a brand separately to Pharmacells™. As the first tenant since the site opened, we’ve been very pleased with the service and attention paid to us by all at Biocity."

It is estimated that there is a one in five chance that individuals will use stem cells in their lifetime to treat a particular medical condition or for diagnostics. Due to recent technological advances, stem cell therapy is now under investigation to treat a much wider range of medical conditions where repair and regrowth of tissue is a critical factor. Diseases and medical conditions which have been shown to have early exciting preliminary benefits from stem cell therapy include diabetes, cancer, heart disease, eye disease, metabolic diseases, gastro intestinal, immune system spinal cord and neurological diseases.

The global market for stem cell products is expected to reach nearly £3.87 billion by 2016.

PCG moved into the Middle East in 2011 where Pharmacells™ co-founder, Dr Neil Fell practices family medicine at his base in Healthpoint Hospital, Abu Dhabi.

www.pharmacells.co.uk
www.biocity-scotland.co.uk

 

Older News

NovaBiotics secures an additional £3.0 million investment from Woodford Investment Management | 3rd March 2017
Commercial Collaboration Deal for (Oral) Lynovex® | 5th August 2016
NovaBiotics Announces New Data on Cysteamine (Nylexa™) as an Antimicrobial Resistance Breaker in Multi Drug Resistant Bacteria | 18 June 2016
NovaBiotics Highlights Importance of Co-ordinated Approach to Antimicrobial Resistance | 7th June 2016
NovaBiotics Wins Investment of the Year Award | 5 Feb 2016
Lynovex® Activity in CF sputum & Against the Emerging CF Pathogen, Mycobacterium abscessus | 12 Aug 2015
Phase IIa clinical study results for NovaBiotics' Lynovex® presented at the 38th Annual European Cystic Fibrosis Symposium | 12 Jun 2015
Launch of the BEAM Alliance | 9 Jun 2015
NovaBiotics Quoted in "What Investment" on 11 February | 11 Feb 2015
NovaBiotics Raises £5.0 million in a Private Placement from Woodford Investment Management | 19 Jan 2015
NovaBiotics' Dr Deborah O'Neil Named EY UK Health Products & Services Entrepreneur of 2014 | 7 Oct 2014
Showcases increasing investor interest in the global stem cell sector | 22 Sep 2014
NovaBiotics Receives Orphan Drug Status from the US Food and Drug Administration (FDA) for Lynovex® | 16 Sep 2014
Scotland's Pharmacells Group creates 12 new jobs at BioCity Scotland following acquisition by Precious Cells Group, London | 18 August 2014
Precious Cells Biobank Acquires Stem Cell Technology Leader Pharmacells Group | 25 July 2014
NovaBiotics' Dr Deborah O'Neil Wins Entrepreneur of the Year | 27 June 2014
NovaBiotics Initiates Phase IIa Clinical Study for Lynovex in Cystic Fibrosis | 25 June 2014
NovaBiotics' Dr Deborah O'Neil Named EY Scotland Entrepreneur of 2014 | 20 June 2014
NovaBiotics Initiates Development of Orphan Drug in Cystic Fibrosis | 17 December 2013
Pharmacells to expand following funding boost | 24 September 2013
NovaBiotics Enters into Agreement with Taro | 28 August 2013
First patient dosed at Aberdeen Royal Infirmary in major international study | 29 August 2012
Pharmacells in talks to extend reach overseas | 24 January 2012
New hope in cystic fibrosis fight as Scots patients first to test drug | 2 January 2012
NovaBiotics reveals plans for cystic fibrosis drug after EU grants orphan status | 19 December 2011
Pharmacells stores stem cells for teenager paralysed in car crash | 20 October 2011
NovaBiotics Ltd - Presentation at BIO International 2011, Washington DC | 24 June 2011
Launch of Oristem® | 04 June 2011
GBP in Nexxus newsletter, Spring 2011 | 22 March 2011
Patents granted in key territories as Novexatin® moves closer to further clinical development and commercialisation | 21 February 2011
Unblinded Phase IIa Clinical Trial Data Delivers Excellent Results for Novexatin®, Nova... | 5 July 2010
Successful Completion of Phase IIa clinical trial for Novexatin®, IND filing planned for Phase IIb... | 1 May 2010

Latest News

NovaBiotics secures an additional £3.0 million investment from Woodford Investment Management
3rd March 2017

Commercial Collaboration Deal for (Oral) Lynovex®
5th August 2016

NovaBiotics Announces New Data on Cysteamine (Nylexa™)
18th June 2016

NovaBiotics Highlights Importance of Co-ordinated Approach to Antimicrobial Resistance
7th June 2016

NovaBiotics Wins Investment of the Year Award
5th February 2016

Lynovex® Activity in CF sputum & Against the Emerging CF Pathogen, Mycobacterium abscessus
12th August 2015

Phase IIa clinical study results for NovaBiotics' Lynovex® presented at the 38th Annual European Cystic Fibrosis Symposium
12th June 2015

Launch of the BEAM Alliance
9th June 2015

NovaBiotics Quoted in "What Investment" on 11 February
11th February 2015

NovaBiotics Raises £5.0 million in a Private Placement from Woodford Investment Management
19th January 2015

NovaBiotics' Dr Deborah O'Neil Named EY UK Health Products & Services Entrepreneur of 2014
7th October 2014

Showcases increasing investor interest in the global stem cell sector
22nd September 2014

NovaBiotics Receives Orphan Drug Status from the US Food and Drug Administration (FDA) for Lynovex®
16th September 2014

Scotland's Pharmacells Group creates 12 new jobs at BioCity Scotland following acquisition by Precious Cells Group, London
18th August 2014

Precious Cells Biobank Acquires Stem Cell Technology Leader Pharmacells Group
25th July 2014